Figure 5
Summary of bleeding phenotype produced by a panel of anti-A2 and anti-C2 MAbs. Light gray, no bleeding phenotype; dark gray, bleeding phenotype. *Inhibitor titer at experimental dose of MAb.
Summary of bleeding phenotype produced by a panel of anti-A2 and anti-C2 MAbs. Light gray, no bleeding phenotype; dark gray, bleeding phenotype. *Inhibitor titer at experimental dose of MAb.
